euro adhoc: Sartorius AG / Financial Figures/Balance Sheet / Order intake (pro forma) rose 7.1%; currency-adjusted: +9.5% | Operating earnings above the previous year´s | Integration of Stedim progres

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Figures for the first nine months 2007

31.10.2007

For the first time, the Sartorius Group is announcing the quarterly
results for a reporting period after the combination of the Sartorius
Biotechnology Division with former Stedim S.A. The figures for order
intake, sales revenue and earnings of the Biotechnology Division and
the Group have therefore been growing on new levels. Thus, nine-month
order intake (pro forma) for the Sartorius Group in 2007 climbed
26.4% relative to the figure published a year ago. For sales revenue,
the corresponding increase was 21.7%. Viewed from this angle, the
Biotechnology Division´s order intake grew 47.2% and its sales
revenue 38.4%. Based on this comparison, consolidated pro forma
earnings before interest, taxes and amortization (EBITA) adjusted for
extraordinary expenses surged 32.5%.

To serve the purpose of ensuring the greatest possible transparency
and comparability of the results of the reporting period with those
of the year-earlier period, the following essentially presents and
describes our corresponding pro forma figures:

Relative to the pro forma year-earlier figure, consolidated pro forma
order intake grew 7.1% to EUR479.7 million (PY: EUR447.9 million).
Currency-adjusted, this corresponds to 9.5% growth. With a pro forma
gain of 8.6% (currency-adjusted: 11.2%) to EUR283.8 million (PY:
EUR261.3 mn), the Biotechnology Division posted considerable growth
in order intake. The Mechatronics Division received orders worth
EUR195.9 million (PY: EUR186.6 mn), which corresponds to a gain of
5.0% (currency-adjusted: 7.2%). At EUR431.9 million (PY: EUR379.4
mn), actual order intake of the Sartorius Group is 13.8%
(currency-adjusted: 16.2%) above the year-earlier figure.

Pro forma consolidated sales revenue was EUR469.9 million (PY:
EUR456.5 mn); this corresponds to growth of 2.9% or,
currency-adjusted, 5.2%. The Biotechnology Division generated pro
forma sales revenue of EUR281.8 million (PY: EUR274.1 mn) and thus
achieved a gain of 2.8% or, currency-adjusted, 5.3%. The Mechatronics
Division grew 3.2% (currency-adjusted: 5.2%) to EUR188.2 million (PY:
EUR182.3 mn). Actual consolidated sales revenue climbed 9.8%
(currency-adjusted: 12,0%) to EUR423.8 million (PY: EUR386.0 mn).

The Group achieved a pro forma underlying EBITA of EUR48.7 million
(PY: EUR48.3 mn); the corresponding EBITA margin was 10.4% (PY:
10.6%). Without the unfavorable impact of currency fluctuations, it
would have reached approx. 11%. The Biotechnology Division
contributed EUR35.2 million (PY: EUR34.7 mn) and the Mechatronics
Division EUR13.5 million (PY: EUR13.6 mn) to these earnings. Actual
EBITA of the Sartorius Group was EUR35.8 million (PY: EUR35.0 mn).

We have adjusted our sales revenue and earnings forecast for 2007
somewhat downward, particularly due to the unfavorable development of
the exchange rates during the past months. For 2007, pro forma sales
revenue for the entire Group is expected to rise to over EUR630
million (previous forecast: EUR650-670 mn) to which the Biotechnology
Division will contribute more than EUR375 million and the
Mechatronics Division more than EUR255 million.

Based on this expected growth and considering the negative impact of
about 0.5 of a percentage point on the EBITA margin due to the
devaluation of the U.S. dollar, we assume that we will reach a pro
forma underlying EBITA margin of around 11.0% to 11.5% (previously
about 12%). For the Biotechnology Division, we anticipate achieving a
pro forma underlying EBITA margin of 13.0% to 13.5% (previously about
14%); for the Mechatronics Division, this figure is expected to reach
8.5% to 9.0% (previously about 9%). This forecast does not include
effects entailed by selling Sartorius Bearing Technology GmbH.

For fiscal 2008, the company expects to post gains in sales revenue
and profitability for both divisions. The Biotechnology division
anticipates sales revenue to grow more than 12,0% in constant
currencies. Sales revenue in constant currencies for the Mechatronics
division is estimated to grow more than 5%. In both divisions, EBITA
is targeted to increase overproportionately, so this margin for the
entire Group is anticipated to rise to approximately 12,0%.

end of announcement euro adhoc 31.10.2007 15:37:52
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / official dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade